Clinical Trials Browser

Recruiting × Recurrence × Gemcitabine × Clear all

NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

100 enrolled

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04984837 2026-04-20

Study of Lacutamab in Peripheral T-cell Lymphoma

Phase 2 Recruiting

56 enrolled

Lymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT06522737 2026-04-06

TERZO

Phase 3 Recruiting

124 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT07221253 2026-03-17

AB02

Phase 3 Recruiting

1,100 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT05300282 2026-01-28

FIL_A-BEGEV

Phase 1/2 Recruiting

122 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT06976190 2026-01-20

Magic-C002

Phase 3 Recruiting

446 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Phase 2 Recruiting

130 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02889666 2024-04-17

CCODG-NSCLC

Phase 1 Recruiting

500 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence